Human Papilloma Virus Awareness Among Hispanic Females with Inflammatory Bowel Disease by José E. Rivera-Acosta et al.
Human Papilloma Virus Awareness Among Hispanic
Females with Inflammatory Bowel Disease
José E. Rivera-Acosta1 & Maysabel Aponte1 & Irene Villamil1 &
Josefina Romaguera1 & Ana P. Ortiz2 & Esther A. Torres1
Received: 2 January 2015 /Revised: 18 March 2015 /Accepted: 6 April 2015 /Published online: 22 April 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Women with inflammatory bowel disease (IBD)
may be at increased risk of human papilloma virus (HPV)
infection and HPV-related malignancies, as many are immu-
nocompromised secondary to the use of immunosuppressant
agents. Several studies have addressed the knowledge about
cervical cancer risk factors in different populations, particular-
ly HPV infection and its association with cervical malignan-
cies; most of these studies show poor patient knowledge. The
purpose of this study is to describe the knowledge of females
with IBD about HPV infection and the HPV vaccine. We
performed a cross-sectional study in 147 consecutive patients
attending the clinics of the University of Puerto Rico Center
for IBD from 2009 to 2010. An interviewer-administered
questionnaire was used to collect information on demo-
graphics, lifestyles, and HPV-related knowledge of partici-
pants. Bivariate analysis using the chi-square statistics and
Fisher’s exact test was used to examine factors associated with
HPVawareness. The mean age of participants was 36.6 years
(SD=13.91 years). Three fourth (77 %) of women had aware-
ness of the existence of HPV, and 58 % did know about the
existence of HPV vaccines. Among those who had heard
about HPV, 79.6 % knew that HPV can cause cervical cancer,
and 57.5 % knew that the virus is sexually transmitted.
Among those who knew of the vaccine, 75.3 % learned about
its existence through the media, while only 15.3 %, through
their health-care provider. Only three women within recom-
mended ages (2 %) had been vaccinated against HPV, al-
though 50 % of participants indicated that they would
definitely/probably vaccinate against HPV in the future. A
significant trend was observed, where more educated women
were more likely to have heard of HPV (p for trend=0.0017).
Women who were high school graduates/some college (OR=
6.63, 95 % CI=1.71–25.66) and those with at least an associ-
ate degree (OR=11.69, 95%CI=3.05–45.89) weremore like-
ly to be aware of the HPV vaccine than women without a high
school degree. Our study documents poor knowledge of HPV
and HPV vaccine in this population of IBD patients in Puerto
Rico. Although vaccination coverage is low in this population,
women are receptive to the possibility of vaccination in the
future. Given that this population may be at an increased risk
of HPV infection and related morbidities, education and vac-
cination programs should be promoted among them.
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Introduction
Human papilloma virus (HPV) is the primary etiologic agent
for the development of cervical cancer and cervical dysplasia,
along with other premalignant and malignant conditions of the
vagina, vulva, and cervix. HPV has been also associated to
anorectal, oropharyngeal, and head and neck cancer. It is esti-
mated that 20 million Americans are infected with this virus,
and a recent study has calculated the prevalence in women
aged 14–59 years at 42.5 % [1]. Several studies have found
that patients with inflammatory bowel disease (IBD) have a
higher risk of developing cervical dysplasia [2, 3] compared
with healthy women. IBD consists of several chronic
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inflammatory conditions that affect the gastrointestinal tract,
being Crohn’s disease and ulcerative colitis the most frequent.
These patients often require immunosuppressive therapy to
control symptoms and disease progression. The risk of cer-
vical dysplasia in IBD patients might be related to the
use of immunosuppressive therapy in a high percent of
these patients.
Cervical cancer has a major impact in females, particularly
in developing countries where it is one of the leading causes of
cancer death annually. According to recent estimates, 530,000
new cases of cervical cancer occur each year in women and
275,000 died of this disease in 2008 [4]. Latin America has
been recognized as an area of high incidence rate of cervical
cancer. The mortality rate associated with this malignancy is
higher in Latin American countries when compared with other
developed countries. This malignancy is potentially prevent-
able by the establishment of screening programs that detect
early cervical abnormalities and, more recently, by the avail-
ability of vaccination against HPV. Two HPV vaccines
(Gardasil® and Cervarix®) were approved on 2006 as an ef-
fective way for primary prophylaxis of cervico-vaginal malig-
nancies. These HPV vaccines target HPV 16 and 18 serotypes,
which account for approximately 70 % of all cervical cancers
[5]. In view of the proved efficacy of vaccination, the Pan
American Health Organization endorsed the implementation
of HPV vaccination on Latin America and the Caribbean in
2008 [6]. Few studies have assessed HPV vaccination rates in
Latin America or the Caribbean, and there is no population-
based study assessing HPV vaccination rate in Puerto Rico. A
review article by Luciani et al. in 2011 found that compliance
with the vaccination rate for the three recommended doses is
only 27 % in the USA compared with 90 % for only the first
shot [7]. Among the possible reasons for HPV vaccination rate
incompliance are financial constraints, cultural belief about
prophylaxis of sexually transmitted disease, poor access to
health-care services, and poor knowledge and awareness
about HPVand cervical cancer risk.
Several studies have demonstrated poor knowledge about
HPV and its association with cervical cancer in the Hispanic
population [8–10]. Hispanic women in the USA have the
highest cervical cancer incidence rates compared with other
ethnic groups [11]. Despite being a high-risk population, there
is no study about the knowledge and attitudes about HPV
infection and other cervical cancer risk factors in Hispanic
women with IBD. In a high-risk population, determining pa-
tient knowledge and attitudes will help in the design of health-
directed initiatives that positively impact prevention, prophy-
laxis, and surveillance.
In view of the close medical follow-up demanded for pa-
tient with chronic inflammatory conditions frequently requir-
ing immunosuppressive medication, it would be expected that
young women with IBD were more aware of routine health
maintenance medical care, such as HPV vaccination and
cervical cancer prevention. This study describes the knowl-
edge about HPV infection and cervical cancer risk factors in a
cohort of Hispanic women with IBD. Factors associated with
HPVawareness and HPV vaccine awareness were analyzed.
Methods
This cross-sectional descriptive study was performed at the
UPR Center for Inflammatory Bowel Diseases clinics from
February 2009 until June 2010. The study had approval from
the University of Puerto Rico Medical Sciences Campus In-
stitutional Review Board. The research coordinator identified
potential participants among patients attending the clinics. All
women older than 15 years with established diagnosis of IBD
evaluated at the clinic were invited to participate in the study.
From approximately 170 subjects invited to participate, 147
(86.5 %) women agreed to participate and were recruited. All
study participants provided informed consent at the clinic. For
subjects under 21 years old, informed consent was obtained
from both the subject and the parents or legal guardian. After
consent, research personnel administered a survey to the study
participants at the clinic. The survey was administered in
Spanish, the native language of all the participants. Estimated
time of completion of the survey was 25 min. Surveys were
identified with a code to protect confidentiality. The survey
included questions about demographic information (age, place
of birth, household income, education level, and civil status),
lifestyle (use of tobacco), medical history (health mainte-
nance, past medical diseases, history of sexually transmitted
diseases), reproductive health (number of pregnancies, age at
first pregnancy, age at first coitus, last menses, previous Pap
smear results, history of abnormal Pap smear, use of contra-
ceptive methods), sexual practices (age at first sexual encoun-
ter, number of partners), knowledge about HPV and other
sexually transmitted diseases (STDs), and HPV vaccination
history (knowledge about HPV vaccine, vaccine administra-
tion, etc.). In the education groups, participants were classified
into those who did not complete high school education (no
high school degree), those who completed high school but did
not complete a college degree (high school graduate/no col-
lege degree), and those who obtained a college degree and/or
completed postgraduate education (college degree or above).
Civil status was classified as those who reported being single
and in no romantic relationship, those married or in a romantic
relationship, and those divorced or widowed. HPVawareness
was evaluated with questions as follows: ‘Have you ever
heard about the Human Papilloma Virus?’ (yes or no). HPV
vaccine awareness was evaluated with the following question:
‘Have you ever heard about the existence of a Human Papil-
loma Virus vaccine?’ (yes or no). Other statements that
reflected knowledge about symptoms of infection with HPV
or cervical cancer and lifestyles that may increase the risk of
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HPV infection were also evaluated. This survey is a modifi-
cation of a survey used by Colón-Lopez et al. to assess HPV
awareness and knowledge on a Hispanic population [12].
Data from the study was recorded in a database designed
with the use of Epi Info™, version 3.3.2. [13]. Statistical anal-
yses were performed using SAS® version 8e for Windows
[14]. Frequency distributions for categorical variables and
summary measures for continuous variables were performed
to describe the data. Chi-square and Fisher’s exact tests were
used to determine the bivariate associations of demographic,
age, socioeconomical status, education level, and participants’
HPVawareness and HPV vaccine awareness [15]. Multivari-
ate logistic regression models were also used to assess these
associations. Interaction terms within the logistic regression
model were evaluated with the likelihood ratio test [16].
Results
Themean age of participants was 36.6 years (SD=13.91 year).
Demographic characteristics are outlined in Table 1. Most of
the participants reported to be born in Puerto Rico (91.8 vs.
8.2 % in USA); however, all participants were of Puerto Rican
ethnicity. Overall, 53.0 % of the participants had Crohn’s dis-
ease, 42.9 % had ulcerative colitis, and 4.1 % indeterminate
IBD. Overall, 86.5 % of the participants reported history of
sexual intercourse, 19.9 % had an age of first coitus <16 years,
and 8.2 % had a history of STDs. Approximately 20 % of the
participants reported no previous Pap smear, and 18 % report-
ed being diagnosed with an abnormal Pap smear in their life-
time. From all the 147 participants, almost one fourth (23.1 %)
of the women (34 participants) had never heard of HPV, and
42.2 % did not know about the existence of HPV vaccines.
Table 2 shows the percent of statements answered correctly by
participants about HPV general knowledge and risk factors for
HPV infection. Those participants who reported awareness
about HPV (n=113) answered general questions about HPV
knowledge and risk factors. Among those who had ever heard
about HPV, 79.6 % knew that HPV can cause cervical cancer
and 57.5 % knew that the virus is sexually transmitted. Only
31.0 % knew that genital warts are caused by HPV while
19.5% of the participants erroneously associated genital warts
with herpes virus. A considerable percentage of the partici-
pants knew about risk factors for HPV infection. However,
only half of the participants recognized that first coitus before
the age of 16 years is an important risk factor for HPV infec-
tion. Most of the participants identified havingmultiple sexual
partners and unprotected sex as important risk factors.
Table 3 describes factors associated to HPVand HPV vac-
cine awareness. Overall, 76.9 % of women had ever heard of
HPV, and 57.8% were aware of the existence of HPV vac-
cines. Younger women (15–29 years) and those with higher
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educational attainment (college graduates) had increased
awareness of HPVand the HPV vaccine (p<0.05).
Among those who knew of the vaccine, 75% learned about
its existence through the media, while only 17% through their
physician/health care professional. Only 3 women of the 147
participants (2 %) had been vaccinated against HPV. This
represents only 5 % compliance (three of 56 participants
who were 9–26 years old) with the recommendations of the
Advisory Committee for Immunization Practices [17]. De-
spite the low reported compliance with HPV vaccination,
50 % of women indicated that they would definitely/
probably vaccinate against HPV in the future (data not
shown).
Table 3 compares the bivariate association between several
variables and HPV and HPV vaccine awareness. Results
showed that women with higher education were more proba-
ble to be aware of HPV and HPV vaccine than women with
less education (p=0.005 and p=0.0002, respectively). No
other covariate was significantly (p<0.05) associated with
HPV and HPV vaccine awareness in bivariate analysis. In
age-adjusted logistic regression analysis (Table 4), a signifi-
cant trend was observed where more educated women were
more likely to have heard of HPV (p for trend=0.0017).
Women who were high school graduates/some college
(OR=6.63, 95 % CI=1.71–25.66) and those with at least an
associate degree (OR=11.69, 95 % CI=3.05–45.89) were
more likely to be aware of the HPV vaccine than women
without a high school degree. No significant interaction was
observed between age and educational attainment within the
model (χ2=1.67, p>0.05).
Discussion
Patients with chronic conditions requiring immunosuppres-
sive therapy, such as a patient with IBD, need a more struc-
tured and regular follow-up by medical providers to address
different special health needs. The comprehensive manage-
ment of these patients includes special attention to routine
health management recommendations like vaccination. In
IBD patients, HPV vaccine should be encouraged in view of
the foreseeable risk of cervical cancer and the proven benefits
of vaccination. It would be expected that young women with
IBD were more aware of routine health maintenance medical
care, like HPV vaccination and cervical cancer prevention.
However, this study demonstrates low awareness about HPV
and HPV vaccine in women with IBD evaluated in the UPR
Center for Inflammatory Bowel Diseases. These findings are
comparable with other studies in Hispanic populations. A
study performed by Tortolero et al. found similar levels of
Table 1 (continued)
Frequency Percent
Don’t know 1 0.7
HPV vaccination participants 9–26 years oldd
Yes 3 5.4
No 53 94.6
a n=146; one participant refused to answer
b n=126; 21 participants refused to answer or had no history of sexual
intercourse
c n=141; six participants refused to answer
d n=56; number of participants between 9 and 26 years old
Table 2 Percent of correct answered statement related to HPV knowledge in participants who reported awareness of HPV (N=113)
Correct Incorrect Don’t know
HPV is the virus that causes herpes 55 (48.7 %) 13 (11.5 %) 45 (39.8 %)
Genital warts are caused by HPV 35 (31.0 %) 32 (28.3 %) 46 (40.7 %)
HPV can cause cervical cancer 90 (79.6 %) 1 (0.9 %) 22 (19.5 %)
Regular Pap test is the best way to prevent complications caused by HPV 100 (88.5 %) 6 (5.3 %) 7 (6.2 %)
A normal Pap test means that the woman is not infected with HPV 28 (24.8 %) 54 (47.8 %) 31 (27.4 %)
Changes in Pap test may indicate infection with HPV 68 (60.2 %) 18 (15.9 %) 27 (23.9 %)
Genital warts are caused by herpes virus 22 (19.5 %) 45 (39.8 %) 46 (40.7 %)
HPV may cause cancer 92 (81.4 %) 2 (1.8 %) 19 (16.8 %)
Pap test almost always detects HPV 61 (54.0 %) 17 (15.0 %) 35 (31.0 %)
At present, there is no treatment that cures HPV 23 (20.3 %) 41 (36.3 %) 49 (43.4 %)
HPV is transmitted sexually 65 (57.5 %) 20 (17.7 %) 28 (24.8 %)
Which of the following increase risk of HPV infection?
Initiation of sexual relations before the age of 16 years old 57 (50.4 %) 27 (23.9 %) 29 (25.7 %)
Having multiple sexual partners 91 (80.5 %) 6 (5.3 %) 16 (14.2 %)
That your partners had history of multiple sexual partners 84 (74.3 %) 10 (8.8 %) 19 (16.9 %)
Not using condoms during sexual intercourse 80 (70.8 %) 15 (13.3 %) 18 (15.9 %)
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Table 3 Factors associated with HPVand HPV vaccine awareness
Heard about HPV infection (n=147) Heard of HPV vaccine (n=147)
n (%) p value n (%) p value
Overall 113 76.9 – 84 57.8 –
Sociodemographics
Age 0.08 0.15
≤35 66 82.5 50 62.5
≥36 47 70.6 34 50.8
Education 0.005 0.0002
No high school degree 10 55.6 3 16.7
High school graduate/no college degree 40 70.2 31 54.4
College degree or above 63 87.5 50 69.4
IBD type 0.425 0.398
Crohn’s 63 80.8 48 61.5
Ulcerative colitis 45 71.4 32 50.8
Indeterminate colitis 5 83.3 4 66.7
Current smoking 1.0 1.0
Yes 4 80.0 3 60.0
No 109 76.8 81 57.0
Civil status 0.546 0.628
Single 45 81.8 33 60.0
Married/in romantic relationship 54 74.0 42 57.5
Divorced/widow 14 73.7 9 47.4
Employment status 0.234 0.444
Employed 46 83.6 35 63.6
Unemployed 51 70.8 39 54.2
Student 16 80.0 10 50.0
Socioeconomic status 0.561 0.071
<$24,000 62 74.7 46 55.4
$25,000–$99,000 18 90.0 16 80.0
>$100,000 15 79.0 12 63.2
Unknown 18 75.0 10 41.7
Place of birth 0.474 0.235
PR 105 77.8 75 55.6
USA 8 66.7 9 75.0
Parity (number of live births) 0.491 0.219
0 46 79.3 37 63.8
1–2 38 80.9 28 59.6
≥3 29 70.7 19 46.3
Lifetime number of sexual partners 0.882 0.657
0 15 79.0 9 47.4
1–2 61 75.3 48 59.3
≥3 33 80.5 24 58.5
Age of first coitus (years)a 0.796 0.639
<16 20 80.0 15 60.0
16–21 44 77.2 31 54.4
>21 32 72.7 28 63.6
Abnormal Papb 0.834 0.994
Yes 21 77.8 16 59.3
No 69 75.8 54 59.3
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awareness of HPV in Puerto Rican women over 18 years old
[18]. Another study performed in Puerto Rican men who
attended a sexually transmitted disease clinic showed low
HPV knowledge and awareness [12]. Despite these findings,
small studies have found a high prevalence of abnormal cer-
vical cytology and high-risk HPV infection in Puerto Rican
women in clinic-based samples [19]. Although no population-
based studies about abnormal cervical cytology exist for
Puerto Rican women, a recent population-based study among
women living in the San Juan metropolitan (2010–2013) area
showed that the prevalence of cervical and anal infection was
29.4 % (95 % CI 23.2–36.4 %) and 38.6 % (95 % CI 30.1–
47.9 %), respectively [20]. Furthermore, the prevalence of
these findings in Puerto Rican patients with IBD who are at
increased risk of cervical malignancy is unknown.
The finding of poor knowledge about HPV in Hispanics or
Latina women has been documented in several studies. For
example, a study published byMarkham et al. in Latino youth
enrolled in nine alternative high schools in Houston, Texas,
found that HPV knowledge was significantly lower in youths
whose mothers were born outside USAversus youths of USA-
bornmothers [21]. In our study, of those patients who reported
awareness about HPV, only a small proportion recognized that
HPV could be acquired by sexual intercourse and that it may
cause genital warts (57.5 and 31 %, respectively). Participants
with a higher level of education reported more awareness of
HPV (p=0.005). Regression analysis in our study demonstrat-
ed that younger women had higher awareness of HPV and
HPV vaccine. In a similar study performed by Drewry et al.
among Latina immigrants aged 19 to 50 years old, 47 % of
participants reported being aware of HPV [22]. This study was
performed as part of a randomized clinical trial that evaluated
the efficacy of a theory-based and culturally relevant interven-
tion focusing on primary and secondary prevention of cervical
cancer in women self-identified as of Latina ethnicity. They
identified that women aged 40–50 years and women who had
a Pap smear in the last year were more likely to report aware-
ness of HPV. These findings provide information about which
subgroup of our IBD population should be targeted for edu-
cation about HPV infection risk factors and prophylaxis. Fur-
thermore, the analysis of the specific details about HPV infec-
tion showed a significant deficit in general knowledge, em-
phasizing the need to develop adequate education and preven-
tion strategies that can positively impact women with IBD
who are at increased risk of HPVinfection and cervical cancer.
Our study showed ample knowledge about the availability of
HPV vaccine in those participants that reported awareness
about HPV. Although ample knowledge about the vaccine
was shown in our study, only a small percentage learned this
from their health-care provider and vaccination was minimal.
Only three participants reported being vaccinated with HPV
vaccine. This represents only 5 % compliance (three from 56
participants who were 9–26 years old) with the recommenda-
tions of the Advisory Committee for Immunization Practices
[15]. Unfortunately, few studies have analyzed awareness of
HPVand cervical cancer and HPV vaccination in Puerto Rico.
Table 3 (continued)
Heard about HPV infection (n=147) Heard of HPV vaccine (n=147)
n (%) p value n (%) p value
STD history 0.069 0.559
Yes 12 100.0 8 66.7
No 100 74.6 76 56.7
a n=96; 17 patients either refused to answer or had no previous sexual relations
b n=90; 23 patients with no previous Pap
Table 4 Factors associated with
HPVand HPV vaccine awareness Heard about HPV Heard of vaccine
OR (95 % CI) OR (95 % CI)
Age (years)
≤35 1.00 1.00
≥36 0.48 (0.21–1.08)* 0.62 (0.31–1.26)
Education
Less than high school 1.00 1.00
High school/some college 1.96 (0.65–5.95) 6.63 (1.71–25.66)
Associate degree or above 5.85 (1.79–19.08)** 11.69 (3.05–44.89)**
p value for trend 0.0017 0.0002
*p<0.10; p<0.05
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Romaguera et al. [23] described the awareness to HPV and
cervical cancer on a population-based study in 566 Puerto
Rican women aged 16–64 years from a metropolitan area in
Puerto Rico. They found that 64.8 % of the cohort had heard
about HPV and 4.9 % of the participants with indication to
receive the vaccine reported compliance with the recommend-
ed three doses. Most of the participants in this study knew
about the vaccine through the media and less than half through
their primary care providers. A recent qualitative study in
Puerto Rican woman recruited in hospitals in San Juan and
other communities found that concerns about efficacy and, to
some extent, safety of HPV vaccination were associated with
participants’ perception that vaccination had not been well
promoted or recommended by their providers [24].
Several factors may explain the low vaccination compli-
ance in our high-risk IBD population: insurance coverage,
poor referral to vaccination programs, and limited access to
vaccination programs. One of the financial barriers to wide-
spread vaccination is that health insurance coverage of vacci-
nation is not universal in Puerto Rico. Vaccination programs
do not sponsor vaccination for patients 19–26 years old, and
not all private insurances cover vaccination for patients in this
same age range. Also, it is our impression that few primary
providers have the infrastructure to offer vaccination in their
clinics. This might be related to the increasing cost of vaccines
and more strict and costly regulations required of providers,
vaccination centers, and programs. Under these circum-
stances, appropriate referral and increasing awareness of vac-
cination in this population should be underscored. In our
study, from 140 participants who reported reasons for not
being vaccinated, almost 40%were not aware of the existence
of the HPV vaccine, 10.7 % considered not being at risk of
HPV, and 5.0 % were worried of possible side effects.
Teitelman et al. identified several barriers for HPV vaccination
in a group of young women aged 13 to 26 years from an
economically disadvantaged urban community [25]. Among
the identified factors were the misconception that the vaccine
might lead to long-term side effects, lack of insurance cover-
ing the HPV vaccine, and difficulties making appointments.
We did not directly address barriers to vaccination in our
study. It is important to characterize these barriers in order to
provide adequate primary prophylaxis to this high-risk popu-
lation. A recent study demonstrated that HPV vaccine elicits
excellent seroconversion in women with IBD using immuno-
suppressive medication, with no severe adverse events [26]. A
similar pilot project by our research group shows similar re-
sults (unpublished data).
This study has some limitations. This is a cross-sectional
study, and no causal relationship can be established in terms of
knowledge of HPV and cervical cancer risk factors and the
actual risk of HPV infection and cervical cancer risk. This
study included a relatively small sample of patients limiting
the generalization of findings obtained in subgroup analysis.
This specific limitation might be addressed in a well-designed
population-based study. We had limited gynecologic informa-
tion of study participants and were unable to establish the
prevalence of HPV infection and cervico-vaginal abnormali-
ties in the women that visited our clinic. In addition, we were
unable to include a healthy control group to compare the find-
ings with those of the IBD patients. However, a similar study
has been performed in Puerto Rican womenwithout IBD [18].
Conclusion
Awareness of HPV risk factors and HPV vaccination is unsat-
isfactory in this underserved population. Our study illustrates
this medical issue in women with IBD evaluated in the UPR
Center for Inflammatory Bowel Diseases. There is a need to
develop education and vaccination programs that can directly
impact this high-risk population; targeted education efforts
should focus on women with reduced educational attainment.
Physicians and health-care workers who care for IBD patients
should encourage vaccination, preferably before administra-
tion of immunosuppressive medications. Also, it is important
that physicians and health-care workers who care for women
with IBD encourage compliance with current endorsed
cervico-vaginal cancer surveillance recommendations, based
on age and risk factors. This is particularly important for gas-
troenterologists closely involved in the treatment of IBD. De-
spite the paucity of scientific data about the most appropriate
surveillance in women with IBD using immunosuppressive
medication, it is our opinion that this group should be consid-
ered at high risk for malignancy. Furthermore, cervical cancer
surveillance may be more important in women older than 26,
with no previous history of HPV immunization, who may
have more cumulative exposure to immunosuppressive drugs
in view of length of disease and in whom vaccination is cur-
rently not endorsed by current clinical guidelines. How cost-
effective might vaccination be in women with IBD older than
26 years old is an undefined topic.
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